問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Taipei Tzu Chi Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 231New Taipei CitySindian

Recruiting Trial

24Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

70Cases

2012-05-01 - 2013-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2012-08-01 - 2015-08-31

Phase III

Randomized, Double-blind, Parallel- group, Placebo-controlled, Confirmatory Study of SM-13496 (lurasidone HCl) in Patients with Schizophrenia <Phase 3>

  • Condition/Disease

    schizophrenia

  • Test Drug

    SM-13496

Participate Sites
13Sites

Terminated13Sites

黃宗正
National Taiwan University Hospital

Division of Psychiatry

2016-06-03 - 2019-06-03

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

2019-09-01 - 2022-09-22

Phase III

A double-blind, placebo-controlled,randomized withdrawal, multicenter clinical trial evaluating the efficacy, safety, and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in bipolar I disorder patients whose current episode is manic or depressive, with or without mixed features

  • Condition/Disease

    Bipolar I disorder

  • Test Drug

    Cariprazine

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2019-10-01 - 2021-01-26

Phase III

A double-blind, placebo-controlled, randomized withdrawal, multicenter clinical trial evaluating the efficacy, safety, and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in patients with schizophrenia.

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Cariprazine

Participate Sites
3Sites

Not yet recruiting2Sites

Study ended1Sites

2021-03-15 - 2022-06-07

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2012-07-01 - 2020-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2009-01-20 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2016-04-01 - 2019-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2007-05-30 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB